Zobrazeno 1 - 10
of 33
pro vyhledávání: '"63"'
Autor:
Elke Verhey, C. Janneke van der Woude, Bettina E. Hansen, Hendrik M. van Dullemen, Ad A. van Bodegraven, Maurice G. Russel, Pieter Dewint, Bas Oldenburg, Marieke Pierik, Cyriel I J Ponsioen, Daniel W. Hommes
Publikováno v:
Gut, 63(2), 292-299. BMJ Publishing Group
Gut, 63(2), 292-299
Gut, 63(2), 292-299. BMJ PUBLISHING GROUP
Dewint, P, Hansen, B E, Verhey, E, Oldenburg, B, Hommes, D W, Pierik, M, Ponsioen, C I J, van Dullemen, H M, Russel, M, van Bodegraven, A A & van der Woude, C J 2014, ' Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI) ', Gut, vol. 63, no. 2, pp. 292-299 . https://doi.org/10.1136/gutjnl-2013-304488
Gut, 63(2), 292-299
Gut, 63(2), 292-299. BMJ PUBLISHING GROUP
Dewint, P, Hansen, B E, Verhey, E, Oldenburg, B, Hommes, D W, Pierik, M, Ponsioen, C I J, van Dullemen, H M, Russel, M, van Bodegraven, A A & van der Woude, C J 2014, ' Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI) ', Gut, vol. 63, no. 2, pp. 292-299 . https://doi.org/10.1136/gutjnl-2013-304488
Objective To assess whether a combination of adalimumab and ciprofloxacin is superior to adalimumab alone in the treatment of perianal fistulising Crohn's disease (CD).Design Randomised, double-blind, placebo controlled trial in eight Dutch hospitals
Autor:
Van Der Valk, Mirthe Emilie, Mangen, Marie Josée J, Leenders, Max, Dijkstra, Gerard, Van Bodegraven, Ad A., Fidder, Herma H., De Jong, Dirk J., Pierik, Marieke, Van Der Woude, C. Janneke, Romberg-Camps, Mariëlle J L, Clemens, Cees H M, Jansen, J.M., Mahmmod, Nofel, Van De Meeberg, Paul C., Van Der Meulen-De Jong, Andrea E., Ponsioen, Cyriel Y., Bolwerk, Clemens J M, Vermeijden, J. Reinoud, Siersema, Peter D., Van Oijen, Martijn G H, Oldenburg, Bas, LS IRAS EEPI GRA (Gezh.risico-analyse), IRAS RATIA-SIB, Risk Assessment of Toxic and Immunomodulatory Agents
Publikováno v:
van der Valk, M E, Mangen, M J J, Leenders, M, Dijkstra, G, van Bodegraven, A A, Fidder, H H, de Jong, D J, Pierik, M, van der Woude, C J, Romberg-Camps, M J L, Clemens, C H M, Jansen, J M, Mahmmod, N, van de Meeberg, P C, Jong, A, Ponsioen, C Y, Bolwerk, C J M, Vermeijden, J R, Siersema, P D, van Oijen, M G H & Oldenburg, B 2014, ' Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF alpha therapy: results from the COIN study ', Gut, vol. 63, no. 1, pp. 72-79 . https://doi.org/10.1136/gutjnl-2012-303376
Gut, 63(1), 72-79. BMJ PUBLISHING GROUP
Gut, 63(1), 72-79. BMJ Publishing Group
Gut, 63, 1, pp. 72-9
Gut, 63(1), 72-79
Gut, 63, 72-9
Gut, 63(1), 72. BMJ Publishing Group
Gut, 63(1), 72-79. BMJ PUBLISHING GROUP
Gut, 63(1), 72-79. BMJ Publishing Group
Gut, 63, 1, pp. 72-9
Gut, 63(1), 72-79
Gut, 63, 72-9
Gut, 63(1), 72. BMJ Publishing Group
Item does not contain fulltext OBJECTIVE: The introduction of anti tumour necrosis factor-alpha (anti-TNFalpha) therapy might impact healthcare expenditures, but there are limited data regarding the costs of inflammatory bowel diseases (IBD) followin
Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy
Autor:
Edith Gavis, Zachariah M. Henseler, Patrick M. Gillevet, Andrew Fagan, Masoumeh Sikaroodi, Tasha M. Santiago-Rodriguez, Michael Fuchs, Phillip B. Hylemon, Jasmohan S. Bajaj, Amirhossein Shamsaddini, Tonya Ward, Dan Knights, Chathur Acharya
Publikováno v:
Gut. 70:1162-1173
ObjectiveAltered bacterial composition is associated with disease progression in cirrhosis but the role of virome, especially phages, is unclear.DesignCross-sectional and pre/post rifaximin cohorts were enrolled. Cross-sectional: controls and cirrhot
Autor:
Nicholas J. Talley, Lars Engstrand, Peter T. Schmidt, Lars Agréus, Luisa W. Hugerth, Anna Forsberg, Anna Andreasson, Lars Kjellström
Publikováno v:
Gut. 69:1076-1084
ObjectiveThe ethiopathogenesis of irritable bowel syndrome (IBS) is unknown. While a link to the gut microbiome is postulated, the heterogeneity of the healthy gut makes it difficult to draw definitive conclusions. We aimed to describe the faecal and
Publikováno v:
Gut. 39(4)
BACKGROUND: Various histological classifications developed for nodal lymphomas failed to be of value in extranodal lymphomas. More recently, gastric lymphoma is considered to represent a distinctive group derived from mucosa associated lymphoid tissu
Autor:
Tali Bdolah-Abram, Amir Schechter, Ron Shaoul, Oren Ledder, Raanan Shamir, Dan Turner, Eyal Shteyer, Christopher E.M. Griffiths, Juan Cristóbal Gana
Publikováno v:
Gut. 64:580-588
Data to support treatment algorithms in ambulatory paediatric UC are scarce. We aimed to explore the 1 year outcome in an inception cohort of paediatric UC patients and to identify early predictors of good outcome that might serve as short term treat
Autor:
Paul Fockens, Esther M. Stoop, Patrick M.M. Bossuyt, Thomas R. de Wijkerslooth, Roderik A. Kraaijenhagen, Marjolein van Ballegooijen, Monique E. van Leerdam, Inge Stegeman, Evelien Dekker, Ernst J. Kuipers
Publikováno v:
Gut, 63(3), 466-471. BMJ Publishing Group
Objective Faecal immunochemical testing (FIT) is increasingly used in colorectal cancer (CRC) screening but has a less than perfect sensitivity. Combining risk stratification, based on established risk factors for advanced neoplasia, with the FIT res
Autor:
J Aschenbeck, Jens-Peter Bruhn, A Schröder, Thomas Rösch, Karl Wegscheider, Klaus Balzer, Alireza Aminalai, M Mayr, Gabriela Stange, András Treszl, Guido Schachschal, Ralf Kießlich, Mathias Scheel, R Drossel, Carl-Hermann Bothe, Wolfgang Burmeister, Christina Bähr
Publikováno v:
Gut. 63:458-465
Background As screening colonoscopy becomes more widespread, the costs for histopathological assessment of resected polyps are rising correspondingly. Reference centres have published highly accurate results for endoscopic polyp classification. There
Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study
Autor:
Caspar W. N. Looman, Ernst J. Kuipers, Gerrit A. Meijer, Mark van Blankenstein, M.K. Casparie, Pieter J F de Jonge
Publikováno v:
de Jonge, P J F, Blankenstein, N, Looman, C W N, Casparie, M K, Meijer, G A & Kuipers, E J 2010, ' Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study ', Gut, vol. 59, no. 8, pp. 1030-1036 . https://doi.org/10.1136/gut.2009.176701
Gut, 59(8), 1030-1036. BMJ Publishing Group
Gut, 59(8), 1030-1036. BMJ Publishing Group
Background Reported incidence rates of oesophageal adenocarcinoma (OAC) in Barrett's oesophagus (BO) vary widely. As the effectiveness of BO surveillance is crucially dependent on this rate, its clarification is essential. Methods To estimate the rat
Publikováno v:
Gut. 59:105-110
Recent studies suggest that cardiac dysfunction precedes development of the hepatorenal syndrome. In this follow-up study, we aimed to investigate the relation between cardiac and renal function in patients with cirrhosis and ascites and the impact o